ALAMEDA, Calif., and PARIS, March 6 /PRNewswire/ -- Singulex Inc. announced today a collaboration with Novartis Pharma AG to give Novartis access to Singulex's advanced biomarker detection technology through an Erenna(TM) Technology Access Program (ETAP). Terms of the collaboration were not disclosed. In addition, the company announced the opening of a facility in Paris, France to support the needs of Singulex's collaborators in Europe.
"We have gained tremendous traction with potential pharmaceutical partners in the last year," said Philippe Goix, Ph.D., president and CEO of Singulex. "Establishing this relationship with Novartis further validates the power of our technology in therapeutic efficacy and toxicity programs."
As part of its ETAP partnership with Novartis, Singulex has placed its flagship biomarker detection platform, the Erenna system, at Novartis' Basel, Switzerland facility and will be working with Novartis to develop biomarker assays that have the potential to advance Novartis' drug development programs. Erenna and accompanying assays are designed to measure very low levels and small changes of protein biomarkers across a variety of biological samples from multiple species.
"Among our goals is the establishment of strong collaborations with pharmaceutical companies that will bring advanced technologies to their translational medicine and biomarker programs," continued Goix. "By opening a facility in Europe, we are bringing our strong immunoassay development skills and Erenna technology closer to European partners. We are actively working to expand our footprint across the globe, and this facility does just that."
Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Alameda, California. To learn more about Singulex, please visit us at http://www.singulex.com.
The Erenna(TM) Technology Access Program (ETAP) offers select clients the opportunity to use Singulex's flagship Erenna system to improve and validate their vital immunoassays, adding as much as 1-3 logs of improvement in sensitivity and providing less than 20% coefficient of variability. ETAP includes the Erenna system, which is designed to detect and count single molecules, customized immunoassay development services, reagents, software and direct and personal client service.
CONTACT: Carolyn Hawley, +1-619-849-5375, email@example.com, for
Web site: http://www.singulex.com/